A Phase I/II trial of Cetuximab, Carboplatin and Radiotherapy for patients with locally advanced Head and Neck Squamous Cell Carcinoma.
The purpose of this study is to assess the safety and feasibility of combining radiotherapy and carboplatin (a chemotherapy drug) with a new drug called cetuximab in patients with locally advanced head and neck cancer
Primary Sponsor
Trans-Tasman Radiation Oncology Group (TROG)
Final Accrual
60
Trial Chairperson
Assoc Prof June Corry, Peter MacCallum Cancer Centre, VIC
Prof Danny Rischin, Peter MacCallum Cancer Centre, VIC
Clinical Trial Registration
Related Post
28 March, 2025
TROG Awards Recognise Research Excellence
Latest news: 28 March 2025. TROG Members who have
27 March, 2025
TROG 2025 ASM advances inclusivity and innovation
Latest news: 27 March 2025 With a theme of
